Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neovasc Inc (NVCN.TO)

Neovasc Inc (NVCN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 31,932
  • Shares Outstanding, K 22,647
  • Annual Sales, $ 2,092 K
  • Annual Income, $ -35,131 K
  • 60-Month Beta 2.75
  • Price/Sales 5.44
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVCN.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -3.56
  • Most Recent Earnings -0.81 on 06/30/20
  • Next Earnings Date 11/05/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Medical Devices

    TSX Bottom 100 Stocks

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.70
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.95
  • Prior Year -1.23
  • Growth Rate Est. (year over year) +43.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.14 +9.65%
on 10/30/20
3.48 -64.08%
on 10/15/20
-1.59 (-55.99%)
since 09/30/20
3-Month
1.14 +9.65%
on 10/30/20
4.05 -69.14%
on 08/05/20
-2.17 (-63.45%)
since 07/30/20
52-Week
1.14 +9.65%
on 10/30/20
11.20 -88.84%
on 12/31/19
-3.82 (-75.35%)
since 10/30/19

Most Recent Stories

More News
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neovasc Inc. ("Neovasc" or "the Company") (NASDAQ: NVCN) for violations...

NVCN.TO : 1.24 (-12.06%)
NVCN : 0.9249 (-12.75%)
CORRECTING and REPLACING NVCN Equity Alert: Rosen Law Firm Announces Investigation of Securities Claims Against Neovasc Inc. - NVCN

In the fifth paragraph of release issued October 29, 2020 the date should read October 28, 2020 (instead of November 28, 2020).

NVCN.TO : 1.24 (-12.06%)
NVCN : 0.9249 (-12.75%)
NVCN Equity Alert: Rosen Law Firm Announces Investigation of Securities Claims Against Neovasc Inc. - NVCN

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Neovasc Inc. (NASDAQ: NVCN) resulting from allegations that Neovasc...

NVCN.TO : 1.24 (-12.06%)
NVCN : 0.9249 (-12.75%)
Stocks in play: Neovasc Inc.

Today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices ...

NVCN.TO : 1.24 (-12.06%)
Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer(TM) Medical Device for the Treatment of Refractory Angina

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 28, 2020) -  (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that 's (FDA's) Circulatory System...

NVCN : 0.9249 (-12.75%)
NVCN.TO : 1.24 (-12.06%)
Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer(TM) Medical Device for the Treatment of Refractory Angina

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices Advisory Panel...

NVCN : 0.9249 (-12.75%)
NVCN.TO : 1.24 (-12.06%)
US Heart Valve Repair and Replacement Market Size | 2020, Growth Strategies, Opportunity, Challenges, Rising Trends and Revenue Analysis 2025

The delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted...

BSX : 34.29 (+2.36%)
CRY : 16.76 (-3.51%)
LIFE : 3.17 (-3.06%)
MDT : 100.57 (-0.79%)
NVCN.TO : 1.24 (-12.06%)
STJ : 80.82 (+0.16%)
Prosthetic Heart Valve/ Artificial Heart Valve Market Research: Growth Opportunities Regions, Types, Applications, Detail Research for Business Development Insights [2020-2025]

The Prosthetic Heart Valve/ Artificial Heart Valve Market is expected to exceed more than US$ 9 Billion by 2024 at a CAGR of 13% in the given forecast period.

CRY : 16.76 (-3.51%)
EW : 71.69 (-1.67%)
LIVN : 50.33 (-4.39%)
MDT : 100.57 (-0.79%)
NVCN.TO : 1.24 (-12.06%)
Prosthetic Heart Valve Market Research Report by Type, by Offering, by Communication Protocol, by Industry - Global Forecast to 2025 - Cumulative Impact of COVID-19

The Global is expected to exceed more than USD$ 4 Billion by 2024; Growing at a CAGR of more than 9% in the given forecast period.

ABT : 105.07 (+0.07%)
BSX : 34.29 (+2.36%)
CRY : 16.76 (-3.51%)
EW : 71.69 (-1.67%)
LIFE : 3.17 (-3.06%)
NVCN.TO : 1.24 (-12.06%)
STJ : 80.82 (+0.16%)
Neovasc to Report Third Quarter Financial Results on November 5, 2020

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 22, 2020) - (NASDAQ: NVCN) (TSX: NVCN) today announced that it will report financial results for the quarter ended September...

NVCN : 0.9249 (-12.75%)
NVCN.TO : 1.24 (-12.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 1.55
1st Resistance Point 1.48
Last Price 1.24
1st Support Level 1.35
2nd Support Level 1.29

See More

52-Week High 11.20
Fibonacci 61.8% 7.36
Fibonacci 50% 6.17
Fibonacci 38.2% 4.98
Last Price 1.24
52-Week Low 1.14

See More

Business Summary

Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar